Bio-Rad Laboratories, Inc. (BIO) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $254.16 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Cyclical risk: PE expanding 2.5x (earnings normalizing).
Bio-Rad Laboratories develops and markets instruments, reagents, and consumables for life science research (40% of 2025 net sales) and clinical diagnostics (60%), operating directly in 36+ countries. ~60% of sales are international with Europe as the largest region; the company... Read more
Sell if holding. Analyst target reached at $254.16 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Cyclical risk: PE expanding 2.5x (earnings normalizing). Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Score 4.8/10, moderate confidence.
Passes 4/6 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-24Item 5.02LOWStockholders approved the Amended 2017 Incentive Award Plan at the April 21, 2026 annual meeting, adding 335,000 shares and extending expiration to March 18, 2036. Routine compensatory arrangement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $254.16 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Cyclical risk: PE expanding 2.5x (earnings normalizing). Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Prior stop was $242.50. Score 4.8/10, moderate confidence.
Take-profit target: $306.59 (+18.5% upside). Prior stop was $242.50. Stop-loss: $242.50.
Cyclical risk: PE expanding 2.5x (earnings normalizing); Analyst target reached - limited upside remaining; Weak overall score: 4.8/10.
Bio-Rad Laboratories, Inc. trades at a P/E of 10.1 (forward 24.7). TrendMatrix value score: 5.3/10. Verdict: Sell.
10 analysts cover BIO with a consensus score of 3.8/5. Average price target: $303.
What does Bio-Rad Laboratories, Inc. do?Bio-Rad Laboratories develops and markets instruments, reagents, and consumables for life science research (40% of 2025...
Bio-Rad Laboratories develops and markets instruments, reagents, and consumables for life science research (40% of 2025 net sales) and clinical diagnostics (60%), operating directly in 36+ countries. ~60% of sales are international with Europe as the largest region; the company also holds a $5.7B fair-value equity stake in Sartorius AG (38% of ordinary shares).